The rational designed antagonist derived from the complex structure of interleukin-6 and its receptor affectively blocking interleukin-6 might be a promising treatment in multiple myeloma

Biochimie

Volumn 88, Issue 9, 2006, Pages 1265-1273

  Feng, Jiannan ^a   Yang, Zhenhui ^a   Li, Yan ^a   Hu, Meiru ^a   Yu, Ming ^a   Qin, Weisong ^a   Sun, Jian ^a   Shen, Beifen ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

3 D complex structure; Apoptosis; Interleukin 6; Interleukin 6 receptor; Rational design

Indexed keywords

INTERLEUKIN 6 ANTIBODY;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL DIFFERENTIATION; DISEASE COURSE; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; OSTEOPOROSIS; RHEUMATOID ARTHRITIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; INTERLEUKIN-6; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MULTIPLE MYELOMA; RECEPTORS, INTERLEUKIN-6;

EID: 33748777096     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2006.03.003     Document Type: Article

References (45)

1. Kimura T., Wang J., Minamiguchi H., Fujiki H., Harada S., and Okuda K. Signal through gp130 activated by soluble interleukin (IL)-6receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors. Stem Cells 18 (2000) 444-452
2. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., and Graeve L. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J. 334 (1998) 297-314
3. Taga T., and Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15 (1997) 797-819
4. Ihle J.N., and Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11 (1995) 69-74
5. Dankba B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., Serve H., Berdel W.E., and Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95 (2000) 2630-2636
6. Anderson K.C. Multiple myeloma. Advances in disease biology: therapeutic implications. Semin. Hematol. 38 (2001) 6-10
7. Lauta V.M. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine 16 (2001) 79-86
8. Barille S., Bataille R., and Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur. Cytokine Netw. 11 (2000) 546-551
9. Durandy A., Emilie D., Peuchmaur M., Forveille M., Clement C., Wijdenes J., and Fischer A. Role of IL6 in promoting growth of human-EBV-induced B cell tumors in severe combined immunodeficient mice. J. Immunol. 152 (1994) 5361-5367
10. Bataille R., Barlogie B., and Lu Z.Y. Biologic effects of antiinterleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86 (1995) 685-691
11. Lu Z.Y., Brailly J., Wijdenes J., Bataille R., Rossi J.F., and Klein B. Measurement of whole body interleukin-6 (IL6) production: Prediction of the efficacy of anti-IL6 treatments. Blood 86 (1995) 3123-3131
12. Boulanger M.J., Chow D.C., Brevnova E.E., and Garcia K.C. Hexameric structure and assembly of the interleukin6/IL6 alpha-receptor/gp130 complex. Science 300 (2003) 2101-2104
13. Chow D.C., Brevnova L., He X.L., Martick M.M., Bankovich A., and Garcia K.C. A structural template for gp130-cytokine signaling assemblies. Biochim. Biophys. Acta 1592 (2002) 225-235
14. Yang Z., Feng J., Hu M., Li Y., Yu M., Qin W., and Shen B. A novel hIL-6 antagonist peptide from computer-aided design contributes to suppression of apoptosis in M1 cells. Biochem. Biophys. Res. Commun. 325 (2004) 518-524
15. Yang Z., Feng J., Li Y., Hu M., Song L., Yu M., Qin W., and Shen B. Structure-based design and characterization of a Novel IL-6 antagonist peptide. Mol. Immunol. 42 (2005) 1015-1021
16. Olsson L., and Kaplan H.S. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc. Natl. Acad. Sci. USA 77 (1980) 5429-5431
17. Wang Y.D., Vos.De J., Jourdan M., Couderc G., Lu A.Y., Rossi J.F., and Klein B. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 21 (2002) 2584-2592
18. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., and Hilton D.J. A family of cytokine-inducible inhibitors of signaling. Nature 387 (1997) 917-921
19. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J.N., and Yoshimura A. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18 (1999) 1309-1320
20. Garnier J., Gibrat J.-F., and Robson B. GOR secondary structure prediction method version IV. Methods in Enzymology. R.F. Doolittle Ed. 266 (1996) 540-553
21. Ramachandran G.N., Ramakrishnan C., and Sasisekharan V. Conformation of polypeptides and proteins. J. Mol. Biol. 7 (1963) 95-99
22. Varghese J.N., Moritz R.L., Lou M.Z., Van Donkelaar A., Ji H., Ivancic N., Branson K.M., Hall N.E., and Simpson R.J. Structure of the extracellular domains of the human interleukin-6 receptor alpha-chain. Proc. Natl. Acad. Sci. USA 99 (2002) 15959-15964
23. Gu Z.J., Costes V., Lu Z.Y., Zhang X.G., Pitard V., Moreau J.F., Bataille R., Wijdenes J., Rossi J.F., and Klein B. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 88 (1996) 3972-3986
24. Qin W.S., Feng J.N., Zhang W., Li Y., and Shen B.F. A novel TNFα antagonizing peptide-Fc fusion protein designed based on CDRs of TNFa neutralizing monoclonal antibody. Biochem. Biophys. Res. Commun. 322 (2004) 1024-1028
25. Zhang J.Y., Shen B.F., Li Y., and Sun Y.X. STAT3 exerts two-way regulation in the biological effects of IL6 in M1 leukemia cells. Leuk. Res. 25 (2001) 463-472
26. 2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA 88 (1991) 2648-2652
27. Chen J.K., Capdevila J., and Harris R.C. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol. Cell. Biol. 21 (2001) 6322-6331
28. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., Summer R., Fine A., Quesenberry P.J., and Walsh K. Akt signaling regulates side population cell phenotype via bcrp1 translocation. J. Biol. Chem. 278 (2003) 39068-39075
29. Tetaud C., Falguieres T., Carlier K., Lecluse Y., Garibal J., Coulaud D., Busson P., Steffensen R., Clausen H., Johannes L., and Wiels J. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mAb and verotoxin-1. J. Biol. Chem. 278 (2003) 45200-45208
30. Kim H.J., Lim S.C., Kim S.H., and Kim T.V. Induction of apoptosis and expression of cell cycle regulatory proteins in response to a phytosphingosine derivative in HaCaT human keratinocyte cells. Mol. Cells 16 (2003) 331-337
31. Schwabe M., Zhao J., and Kung H.F. Differential expression and ligand-induced modulation of the human interleukin-6 receptor on interleukin-6-responsive cells. J. Biol. Chem. 269 (1994) 7201-7209
32. Alexanian R., and Dimopoulos M. The treatment of multiple myeloma. N. Engl. J. Med. 330 (1994) 484-489
33. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., and Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N. Engl. J. Med. 335 (1996) 91-97
34. Savino R., Ciapponi L., Lahm A., Demartis A., Cabibbo A., Toniatti C., Delmastro P., Altamura S., and Ciliberto G. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 13 (1994) 5863-5870
35. Ciapponi L., Maione D., Scoumanne A., Costa P., Hansen M.B., Svenson M., Bendtzen K., Alonzi T., Paonessa G., Cortese R., Ciliberto G., and Savino R. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL6 receptor antagonist. Nat. Biotechnol. 15 (1997) 997-1001
36. Hayashi M., Rho M.C., Enomoto A., Fukami A., Kim Y.P., Kikuchi Y., Sunazuka T., Hirose T., Komiyama K., and Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc. Natl. Acad. Sci. USA 99 (2002) 14728-14733
37. Murakami M., Hibi M., Nakagawa N., Nakagawa K., Yasukawa T., Yamanishi K., Taga T., and Kishimoto T. IL6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260 (1993) 1808-1810
38. Paonessa G., Graziani R., Serio S.D., Savino R., Ciapponi L., Lahm A., Salvati A.L., Toniatti C., and Ciliberto G. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signaling. EMBO J. 14 (1995) 1942-1951
39. Decoster E., Cornelis S., Vanhaesebroeck B., and Fiers W. Autocrine tumor necrosis factor (TNF) and lymphotoxin (LT) alpha differentially modulate cellular sensitivity to TNF/LT-alpha cytotoxicity in L929 cells. J. Cell Biol. 143 (1998) 205720-205765
40. Longhi S.A., Miranda M.E., Gobet M.G., and Retegui L.A. A monoclonal antibody recognizing an epitope shared by receptors for growth hormone, prolactin, interleukin2 and interleukin6. Mol. Cell. Biochem. 195 (1999) 235-243
41. Shafarenko M., Amanullah A., Gregory B., Liebermann D.A., and Hoffman B. Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation. Blood 103 (2004) 4259-4267
42. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., and Anderson K.C. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 159 (1997) 2212-2221
43. Ogata A., Chauhan D., Urashima M., Teoh G., Treon S., and Anderson K.C. Blockade of MAPK cascade signaling in interleukin-6 independent multiple myeloma cells. Clin. Cancer Res. 3 (1997) 1017-1022
44. Mosteller R.D., Han J., and Broek D. Identification of residues of the H-ras protein critical for functional interaction with guanine nucleotide exchange factors. Mol. Cell. Biol. 14 (1994) 1104-1112
45. Quilliam L.A., Rebhun J.F., and Castro A.F. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog. Nucleic Acid Res. Mol. Biol. 71 (2002) 391-444